TOXICOLOGY AND CARCINOGENESIS STUDIES OF ELMIRON®(CAS NO. 37319-17-8) IN F344/N RATS AND B6C3F1MICE (GAVAGE STUDIES)

NTP Technical Report on the Toxicology and Carcinogenesis Studies Series

Volumn TR-512, Issue , 2004, Pages 1-300

  Abdo, K M ^a   Bristol, D W ^a   Bucher, J R ^a   Hailey, J R ^a   Haseman, J K ^a   Maronpot, R R ^a   Morgan, D L ^a   Orzech, D P ^a   Peddada, S D ^a   Rao, G N ^a   Roycroft, J H ^a   Smith, C S ^a   Travlos, G S ^a   Witt, K L ^a   Wenk, M L ^a   Pippin, L L ^a   Hejtmancik, M R ^a   Singer, A W ^a   Hardisty, J F ^a   Brecher, S ^a   Nold, J B ^b   Brix, A E ^c   Flake, G P ^d   Hamilton, B F ^e   Herbert, R A ^d   Little, P B ^b   Nyska, A ^d   Pearse, G ^d   Ryan, M J ^f   Tomlison, L ^g   Willson, G ^c   Grumbein, S L ^f   Wolf, D ^h   Crockett, P W ^a   Betz, L J ^a   McGowan, K P ^a   Scott, J T ^a   Gunnels, S R ^a   Barker, M P ^a   Carver, P H ^a   Gideon, P A ^a   Harper, L M ^a   Serbus, D C ^a   more..

^a ILS Inc ^*

^b Pathology Associates International

^c EXPERIMENTAL PATHOLOGY LABORATORIES INC   (United States)

^d National Toxicology Program

^e GLAXOSMITHKLINE   (United Kingdom)

^f BATTELLE MEMORIAL INSTITUTE   (United States)

^g NORTH CAROLINA STATE UNIVERSITY   (United States)

^h Environmental Protection Agency

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70649112184     PISSN: 23788917     EISSN: 23788925     Source Type: Book Series    
DOI: None     Document Type: Review

References (92)

1. Alshak, N.S., Cocjin, J., Podesta, L., van de Velde, R., Makowka, L., Rosenthal, P., and Geller, S.A. (1994). Hepatocellular adenoma in glycogen storage disease type IV. Arch. Pathol. Lab. Med. 118(1), 88-91.
2. Alza Corporation (1998). Elmiron® (pentosan polysulfate sodium): Questions and Answers about Interstitial Cystitis and about Elmiron® Therapy. .
3. Anand, R., Nayyar, S., Galvin, T.A., Merril, C.R., and Bigelow, L.B. (1990). Sodium pentosan polysulfate (PPS), an anti-HIV agent also exhibits synergism with AZT, lymphoproliferative activity, and virus enhancement. AIDS Res. Hum. Retroviruses 62(5), 679-689.
4. Ashby, J., and Tennant, R.W. (1991). Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTP. Mutat. Res. 257, 229-306.
5. Baba, M., Nakajinia, M., Schols, D., Pauwels, R., Balzarini, J., and DeClerc, Q. (1988). Pentosanpolysulfate, a sulfated oligosaccharide is a potent and selective anti-HIV agent in vitro. Antiviral Res. 9, 335-343.
6. Bailer, A.J., and Portier, C.J. (1988). Effects of treatment-induced mortality and tumor-induced mortality on tests for carcinogenicity in small samples. Biometrics 44, 417-431.
7. Bieler, G.S., and Williams, R.L. (1993). Ratio estimates, the delta method, and quantal response tests for increased carcinogenicity. Biometrics 49, 793-801.
8. Bjorck, C.G., Bergqvist, D., Esquivel, C., Nillson, B., and Rudsvik, Y. (1984). Effect of heparin, low molecular weight (LMW) heparin, and a heparin analogue on experimental venous thrombosis in the rabbit. Acta Chir. Scand. 150, 629-633.
9. Boorman, G.A., Montgomery, C.A., Jr., Eustis, S.L., Wolfe, M.J., McConnell, E.E., and Hardisty, J.F. (1985). Quality assurance in pathology for rodent carcinogenicity studies. In Handbook of Carcinogen Testing (H.A. Milman and E.K. Weisburger, Eds.), pp. 345-357. Noyes Publications, Park Ridge, NJ.
10. Cadroy, Y., Dol, F., Caranobe, C., Sie, P., Houin, G., Picard, C., Pereillo, J.M., Maffrand, J.P., and Boneu, B. (1987). Pharmacokinetics of 125I-pentosan polysulfate in the rabbit. Thromb. Res. 48, 373-378.
11. Castagnaro, M., Alroy, J., Ucci, A.A., and Glew R.H. (1987). Lectin histochemistry and ultrastructure of feline kidneys from six different storage diseases. Virchows Arch. B. Cell Pathol. 54, 16-26.
12. Code of Federal Regulations (CFR) 21, Part 58.
13. Cotran, R.S., Kumar, V., and Collins, T. (1999). Genetic disorders. In Pathologic Basis of Disease, pp. 139-187. W.B. Saunders Company, Philadelphia.
14. Cox, D.R. (1972). Regression models and life-tables. J. R. Stat. Soc. B34, 187-220.
15. Crawford, B.D. (1985). Perspectives on the somatic mutation model of carcinogenesis. In Advances in Modern Environmental Toxicology. Mechanisms and Toxicity of Chemical Carcinogens and Mutagens (M.A. Mehlman, W.G. Flamm, and R.J. Lorentzen, Eds.), pp. 13-59. Princeton Scientific Publishing Co., Inc., Princeton, NJ.
16. Danielson, B., Fellstrom, B., Lindsjo, M., Ljunghall, S., and Wikstrom, B. (1990). New drug to prevent recurrence of renal stone disease. In Proceedings of the 11th Congress of Nephrology. Tokyo.
17. Dawes, J., Prowse, C.V., and Pepper, D.S. (1986). Absorption of heparin, LMW heparin and SP54 after subcutaneous injection, assessed by competitive binding assay. Thromb. Res. 44, 683-696.
18. Dencker, L., Tengblad, A., and Odlind, B. (1985). Preferential localization of 3H-pentosan polysulfate to urinary tract in rats. Acta Physiol. Scand. 124, 351.
19. Dixon, W.J., and Massey, F.J., Jr. (1951). Introduction to Statistical Analysis, 1st ed., pp. 145-147. McGraw-Hill Book Company, Inc., New York.
20. Dunn, O.J. (1964). Multiple comparisons using rank sums. Technometrics 6, 241-252.
21. Dunnett, C.W. (1955). A multiple comparison procedure for comparing several treatments with a control. J. Am. Stat. Assoc. 50, 1096-1121.
22. Esquivel, C.O., Bergqvist, D., Bjorck, C.G., and Nilsson, B. (1982). Comparison between commercial heparin, low molecular weight heparin and pentosan polysulfate on hemostasis and platelets in vivo. Thromb. Res. 28(3), 389-399.
23. Faaij, R.A., Srivastava, N., van Griensven, J.M., Schoemaker, R.C., Kluft, C., Burggraaf, J., and Cohen, A.F. (1999). The oral bioavailability of pentosan polysulphate sodium in healthy volunteers. Eur. J. Clin. Pharmacol. 54(12), 929-935.
24. Fernandez, F., N'guyen, P., Van Ryn, J., Ofosu, F.A., Hirsh, J., and Buchanan, M.R. (1986). Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. Thromb. Res. 43(4), 491-495.
25. Fischer, A.M., Merton, R.E., Marsh, N.A., Williams, S., Gaffney, P.J., Barrowcliffe, T.W., and Thomas, D.P. (1982). A comparison of pentosan polysulfate and heparin. II: Effects of subcutaneous injection. Thromb. Haemost. 47(2), 109-113.
26. Follea, G., Hammandjian, I., Trzeciak, M.C., Neday, C., and Streichenberger, R. (1985). Pentosan polysulphate (SP54)-induced thrombocytopenia. Thromb. Haemost. 54, 108.
27. Forestier, F., Fischer, A.M., Daffos, F., Beguin, S., and Diner, H. (1986). Absence of transplacental passage of pentosan polysulfate during mid trimester of pregnancy. Thromb. Haemost. 56(3), 247-249.
28. Fritjofsson, A., Fall, M., Juhlin, R., Persson, B.E., and Ruutu, M. (1987). Treatment of ulcer and nonulcer interstitial cystitis with sodium pentosan polysulfate: A multicenter trial. J. Urol. 138(3), 508-512.
29. Ghadially, F.N. (1997). Lysosomes. In Ultrastructural Pathology of the Cell and Matrix (F.N. Ghadially, Ed.), pp. 619-802. Butterworth-Heinemann, Boston.
30. Ghosh, P. (1988). Anti-rheumatic drugs and cartilage. In Bailliere's Clinical Rheumatology (P. Brooks, Ed.), Vol. 2, pp. 309-338. Harcourt, London, UK.
31. Ghosh, P. (1999). The pathobiology of osteoarthritis and the rationale for the use of pentosan polysulfate for its treatment. Semin. Arthritis Rheum. 28(4), 211-267.
32. Gouault-Heilmann, M., Payen, D., Contant, G., Intrater, L., Huet, Y., and Schaeffer, A. (1985). Thrombocytopenia related to synthetic heparin analogue therapy. Thromb. Haemost. 54(2), 557.
33. Haagsma, E.B., Smit, G.P., Niezen-Koning, K.E., Gouw, A.S., Meerman, L., and Slooff, M.J. (1997). Type IIIb glycogen storage disease associated with endstage cirrhosis and hepatocellular carcinoma. Hepatology 25(3), 537-540.
34. Halliwell, W.H. (1997). Cationic amphiphilic druginduced phospholipidosis. Toxicol. Pathol. 25, 53-60.
35. Hobbelen, P.M.J., Vogel, G.M.T., Princen, A.W.N., and Meuleman, D.G. (1985). Benefit (antithrombotic)/risk (bleeding) ratio of various heparin(oids) in experimental models in rats. Thromb. Haemost. 54(1), 32.
36. Hollander, M., and Wolfe, D.A. (1973). Nonparametric Statistical Methods, pp. 120-123. John Wiley and Sons, New York.
37. Hutadilok, N., Smith, M.M., Cullis-Hill, D., Brooks, P.M., and Ghosh, P. (1988). Pentosan polysulphate stimulates hyaluronate and DNA synthesis in synovial fibroblasts and partially reduces the suppressive effect of hydrocortisone on fibroblast metabolism. Curr. Ther. Res. 44, 845-860.
38. Integrated Laboratory Systems (ILS) (1990). Micronucleus Data Management and Statistical Analysis Software, Version 1.4. ILS, P.O. Box 13501, Research Triangle Park, NC 27707.
39. Ishioka, T., Kuwabara, N., and Fukuda, Y. (1985). Induction of colorectal adenocarcinoma in rats by amylopectin sulfate. Cancer Lett. 26(3), 277-282.
40. Ishioka, T., Kuwabara, N., Oohashi, Y., and Wakabayashi, K. (1987). Induction of colorectal tumors in rats by sulfated polysaccharides. Crit. Rev. Toxicol. 17(3), 215-244.
41. Joffe, S. (1976). Drug prevention of postoperative deep vein thrombosis. A comparative study of calcium heparinate and sodium pentosan polysulfate. Arch. Surg. 111, 37-40.
42. Jonckheere, A.R. (1954). A distribution-free k-sample test against ordered alternatives. Biometrika 41, 133-145.
43. Kacew, S., Reasor, M.J., and Ruben, Z. (1997). Cationic lipophilic drugs: Mechanisms of action, potential consequences, and reversibility. Drug Metab. Rev. 29(1-2), 355-368.
44. Kaplan, E.L., and Meier, P. (1958). Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53, 457-481.
45. Lippman, M.E., and Wellstein, A. (1992). Inhibition by pentosan polysulfate (PPS) of heparin-binding growth factors released from tumor cells and blockage by PPS of tumor growth in animals. J. Natl. Cancer Inst. 8, 1716-1724.
46. Lullmann-Rauch, R., Pods, R., and Von Witzendorff, B. (1995). Tilorone-induced lysosomal storage of sulphated glycosaminoglycans can be separated from tilorone-induced enhancement of lysosomal enzyme secretion. Biochem. Pharmacol. 49, 1223-1233.
47. McConnell, E.E., Solleveld, H.A., Swenberg, J.A., and Boorman, G.A. (1986). Guidelines for combining neoplasms for evaluation of rodent carcinogenesis studies. JNCI 76, 283-289.
48. McDowell, E.M., and Trump, B.F. (1976). Histologic fixatives suitable for diagnostic light and electron microscopy. Arch. Pathol. Lab. Med. 100, 405-414.
49. MacGregor, I.R., Dawes, J., Paton, L., Pepper, D.S., Prowse, C.V., and Smith, M. (1984). Metabolism of sodium pentosan polysulphate in man-catabolism of iodinated derivatives. Thromb. Haemost. 51(3), 321-325.
50. MacGregor, I.R., Dawes, J., Pepper, D.S., Prowse, C.V., and Stocks, J. (1985). Metabolism of sodium pentosan polysulphate in man measured by a new competitive binding assay for sulphated polysaccharides-comparison with effects upon anticoagulant activity, lipolysis and platelet alpha-granule proteins. Thromb. Haemost. 53(3), 411-414.
51. MacGregor, J.T., Wehr, C.M., Henika, P.R., and Shelby, M.D. (1990). The in vivo erythrocyte micronucleus test: Measurement at steady state increases assay efficiency and permits integration with toxicity studies. Fundam. Appl. Toxicol. 14, 513-522.
52. Maronpot, R.R., and Boorman, G.A. (1982). Interpretation of rodent hepatocellular proliferative alterations and hepatocellular tumors in chemical safety assessment. Toxicol. Pathol. 10, 71-80.
53. Marsh, N.A., Peyser, P.M., Creighton, L.J., Mahmoud, M., and Gaffney, P.J. (1985). The effect of pentosan polysulphate (SP54) on the fibrinolytic enzyme system-a human volunteer and experimental animal study. Thromb. Haemost. 54(4), 833-837.
54. Marshall, J.L., Wellstein, A., Rae, J., DeLap, R.J., Phipps, K., Hanfelt, J., Yunmbam, M.K., Sun, J.X., Duchin, K.L., and Hawkins, M.J. (1997). Phase I trial of orally administered pentosan polysulfate in patients with advanced cancer. Clin. Cancer Res. 12(pt 1), 2347-2354.
55. The Merck Index (1996). 12th ed. (S. Budavari, Ed.), p. 1227. Merck and Company, Whitehouse Station, NJ.
56. Miller, J.A., and Miller, E.C. (1977). Ultimate chemical carcinogens as reactive mutagenic electrophiles. In Origins of Human Cancer (H.H. Hiatt, J.D. Watson, and J.A. Winsten, Eds.), pp. 605-627. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
57. Morrison, D.F. (1976). Multivariate Statistical Methods, 2nd ed., pp. 170-179. McGraw-Hill Book Company, New York.
58. National Toxicology Program (NTP) (1997). Final Report on the Reproductive Toxicity of Elmiron (CAS No. 37319-17-8) Administered by Gavage to Sprague-Dawley Rats. NTIS Order Number: PB97-182604INZ.
59. Nethery, A., Giles, I., Jenkins, K., Jackson, C., Brooks, P., Burkhardt, D., Ghosh, P., Whitelock, J., O'Grady, R.L., Welgus, H.G., and Schrieber, L. (1992). The chondroprotective drugs, Arteparon, and sodium pentosan polysulphate, increase collagenase activity and inhibit stromelysin activity in vitro. Biochem. Pharmacol. 44(8), 1549-1553.
60. Oohashi, Y., Ishioka, T., Wakabayashi, K., and Kuwabara, N. (1981). A study on carcinogenesis induced by degraded carrageenan arising from squamous metaplasia of the rat colorectum. Cancer Lett. 14(3), 267-272.
61. Piegorsch, W.W., and Bailer, A.J. (1997). Statistics for Environmental Biology and Toxicology, Section 6.3.2. Chapman and Hall, London.
62. Portier, C.J., and Bailer, A.J. (1989). Testing for increased carcinogenicity using a survival-adjusted quantal response test. Fundam. Appl. Toxicol. 12, 731-737.
63. Portier, C.J., Hedges, J.C., and Hoel, D.G. (1986). Agespecific models of mortality and tumor onset for historical control animals in the National Toxicology Program's carcinogenicity experiments. Cancer Res. 46, 4372-4378.
64. Prasad, A., Kaye, E.M., and Alroy, J. (1996). Electron microscopic examination of skin biopsy as a costeffective tool in the diagnosis of lysosomal storage disease. J. Child Neurol. 11, 301-308.
65. Rao, G.N. (1996). New diet (NTP-2000) for rats in the National Toxicology Program toxicity and carcinogenicity studies. Fundam. Appl. Toxicol. 32, 102-108.
66. Rao, G.N. (1997). New nonpurified diet (NTP-2000) for rodents in the National Toxicology Program's toxicology and carcinogenesis studies. J. Nutr. 127, 842s-846s.
67. Ruben, Z., Dodd, D.C., Rorig, K.J., and Anderson, S.N. (1989). Disobutamide: A model agent for investigating intracellular drug storage. Toxicol. Appl. Pharmacol. 97(1), 57-71.
68. Ruben, Z., Anderson, S.N., and Kacew, S. (1991). Changes in saccharide and phospholipid content associated with drug storage in cultured rabbit aorta muscle cells. Lab. Invest. 64(4), 574-584.
69. Ruben, Z., Rorig, K.J., and Kacew, S. (1993). Perspectives on intracellular storage and transport of cationic-lipophilic drugs. Proc. Soc. Exp. Biol. Med. 203(2), 140-149.
70. Scully, M.F., Weerasinghe, K.M., Ellis, V., Djazaeri, B., and Kakker, V.V. (1983). Anticoagulant and antiheparin activities of a pentosan polysulphate. Thromb. Res. 31(1), 87-97.
71. Shelby, M.D. (1988). The genetic toxicity of human carcinogens and its implications. Mutat. Res. 204, 3-15.
72. Shelby, M.D., and Witt, K.L. (1995). Comparison of results from mouse bone marrow chromosome aberration and micronucleus tests. Environ. Mol. Mutagen. 25, 302-313.
73. Shelby, M.D., and Zeiger, E. (1990). Activity of human carcinogens in the Salmonella and rodent bone-marrow cytogenetics tests. Mutat. Res. 234, 257-261.
74. Shelby, M.D., Erexson, G.L., Hook, G.J., and Tice, R.R. (1993). Evaluation of a three-exposure mouse bone marrow micronucleus protocol: Results with 49 chemicals. Environ. Mol. Mutagen. 21, 160-179.
75. Shirley, E. (1977). A non-parametric equivalent of Williams' test for contrasting increasing dose levels of a treatment. Biometrics 33, 386-389.
76. Siciliano, M., De Candia, E., Ballarin, S., Vecchio, F.M., Servidei, S., Annese, R., Landolfi, R., and Rossi, L. (2000). Hepatocellular carcinoma complicating liver cirrhosis in type IIIa glycogen storage disease. J. Clin. Gastroenterol. 31, 80-82.
77. Sie, P., Pichon, J., Bouloux, C., Lansen, J., and Boneu, B. (1985). Profibrinolytic effect of pentosan polysulfate (PPS) in vivo. Thromb. Haemost. 54(1), 105.
78. Stefanski, S.A., Elwell, M.R., and Stromberg, P.C. (1990). Spleen, Lymph Nodes, and Thymus. In Pathology of the Fischer Rat (G.A. Boorman, S.L. Eustis, M.R. Elwell, C.A. Montgomery, Jr., and W.F. MacKenzie, Eds.), pp. 369-393. Academic Press, Inc., San Diego.
79. Straus, D.S. (1981). Somatic mutation, cellular differentiation, and cancer causation. JNCI 67, 233-241.
80. Tardy-Poncet, B., Tardy, B., Grelac, F., Reynand, J., Mesmetti, P., Burtrand, J.C., and Guyotat, D. (1994). Pentosan sulfate-induced thrombocytopenia and thrombosis. Am. J. Hematol. 45(3), 252-257.
81. Tarone, R.E. (1975). Tests for trend in life table analysis. Biometrika 62, 679-682.
82. Tennant, R.W., Margolin, B.H., Shelby, M.D., Zeiger, E., Haseman, J.K., Spalding, J., Caspary, W., Resnick, M., Stasiewicz, S., Anderson, B., and Minor, R. (1987). Prediction of chemical carcinogenicity in rodents from in vitro genetic toxicity assays. Science 236, 933-941.
83. Thebault, J.J., Lansen, J., Chigo, C., Bouloux, C., and Maffrana, J.P. (1985). Kinetics of activity and tolerance of pentosane polysulfate (CB8061) in human volunteers. Thromb. Haemost. 54(1), 94.
84. Thonnard-Newman, E., and Bigelow, L.B. (1988). Prophylaxis of migraine with anionic polyelectrolytes. Headache 28, 114-120.
85. Travlos, G.S., Morris, R.W., Elwell, M.R., Duke, A., Rosenblum, S., and Thompson, M.B. (1996). Frequency and relationships of clinical chemistry and liver and kidney histopathology findings in 13-week toxicity studies in rats. Toxicology 107, 17-29.
86. Vinazzer, H. (1984). Clinical and experimental data on the fibrinolytic action of pentosan polysulphate. Haemostasis 14, 122.
87. Wedren, H. (1987). Effects of sodium pentosanpolysulphate on symptoms related to chronic non-bacterial prostatitis. A double-blind randomized study. Scand. J. Urol. Nephrol. 21(2), 81-88.
88. Williams, D.A. (1971). A test for differences between treatment means when several dose levels are compared with a zero dose control. Biometrics 27, 103-117.
89. Williams, D.A. (1972). The comparison of several dose levels with a zero dose control. Biometrics 28, 519-531.
90. Witt, K.L., Knapton, A., Wehr, C.M., Hook, G.J., Mirsalis, J., Shelby, M.D., and MacGregor, J.T. (2000). Micronucleated erythrocyte frequency in peripheral blood of B6C3F1 mice from short-term, prechronic, and chronic studies of the NTP Carcinogenesis Bioassay Program. Environ. Mol. Mutagen. 36, 163-194.
91. Zeiger, E., Anderson, B., Haworth, S., Lawlor, T., Mortelmans, K., and Speck, W. (1987). Salmonella mutagenicity tests: III. Results from the testing of 255 chemicals. Environ. Mutagen. 9 (Suppl. 9), 1-110.
92. Zeiger, E., Haseman, J.K., Shelby, M.D., Margolin, B.H., and Tennant, R.W. (1990). Evaluation of four in vitro genetic toxicity tests for predicting rodent carcinogenicity: Confirmation of earlier results with 41 additional chemicals. Environ. Mol. Mutagen. 16 (Suppl. 18), 1-14.